sintilimab
Jump to navigation
Jump to search
Indications
- non-small cell lung cancer (NSCLC)
- advanced gastric cancer*[3]
- gastroesophageal junction adenocarcinoma*[3]
* aded to chemotherapy
Dosage
- 200 mg every 3 weeks for up to 2 years
Mechanism of action
- fully human IgG4 monoclonal antibody PD-1 inhibitor
More general terms
References
- ↑ Sternberg A Sintilimab Moves Forward With FDA Acceptance of Application in Nonsquamous NSCLC. CancerNetwork. May 18, 2021 https://www.cancernetwork.com/view/sintilimab-moves-forward-with-fda-acceptance-of-application-in-nonsquamous-nsclc
- ↑ Davenport L Triple Therapy for Squamous NSCLC Shows Real-World Clinical Benefit. Medscape. December 23, 2021 https://www.medscape.com/viewarticle/965488
- ↑ 3.0 3.1 3.2 Xu J, Jiang H, Pan Yet al Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer. The ORIENT-16 Randomized Clinical Trial. JAMA. 2023;330(21):2064-2074. Dec 5 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38051328 https://jamanetwork.com/journals/jama/fullarticle/2812482